LAS VEGAS, Nov. 13, 2015 — A low cost, handheld visual electrodiagnostic device cleared by the FDA last spring is now available for demonstration and purchase at the American Academy of Ophthalmology’s annual meeting. Eye physicians, surgeons, and other AAO attendees are invited for demonstrations of the RETeval™ Complete device at LKC Technologies’ booths: Retina Subspecialty Day (#41) and AAO ’15 (#2232).
“As the father of a son totally blind from birth, I’m passionate about making ophthalmic diagnostic services available to everyone,” noted James Datovech, president of LKC Technologies, maker of RETeval devices. “Until now, the diagnostic benefits of objective, functional testing via electrophysiology were limited to ophthalmic practices large enough to support a capital equipment investment of $40,000 or more. In many areas, patients travel long distances, often by plane, to undergo electroretinogram (ERG) or visual evoked potential (VEP) testing. LKC’s mission is to make sophisticated visual diagnostic systems more easily accessible to physicians and their patients, and RETeval ERG/VEP is a huge step in this direction. I’m proud of the LKC scientists and bioengineers whose ingenuity enabled us to introduce these small, lightweight, handheld ERG/VEP devices priced under $15,000.”
LKC’s patented RETeval Complete Option includes 30 Hz Flicker ERG using LKC’s Sensor Strip Skin Electrodes (patent-pending), as well as ISCEV-compliant 5 and 6 step protocols, custom protocols, flash VEP, photopic negative response, s-cone, real-time pupillometry (patented), the ability to test with or without dilation, and other innovative features unique in a lightweight, handheld device at an accessible price point for clinicians. RETeval devices are used in a variety of applications and locations around the world, including:
- Examinations under anesthesia and hospital clinics.
- Remote locations (rural clinics and at the patient’s bedside).
- Offices of ophthalmologists and retinal specialists.
- University and medical research laboratories.
According to the International Society for Clinical Electrophysiology of Vision (ISCEV), referral indications for electrophysiological tests include:
- Confirmation of Neurological or Ophthalmological Diseases, including: inherited retinal degeneration, ocular hypertension/glaucoma, ocular siderosis, retinal detachment, inflammatory ocular diseases, and retinal ischemia.
- Unexplained Vision Loss.
- Pediatric Neurology.
- Detection of Disease or Carrier States of Inherited Visual Disorders including retinitis pigmentosa and congenital stationary night blindness.
- Monitoring health (toxicity).
- Quantitative assessment of visual disease, including uveitis, thyrotoxicosis, and perioperative monitoring.
- Retinal Vascular Disease and Diabetic Retinopathy.
- Assessment of Retinal and Optic Nerve Function Following Trauma including cloudy or opaque media with suspect retinal function and subtle optic nerve or cortical damage after head injury.
Dr. Quentin Davis, LKC’s VP of Operations, added, “Beyond the known conditions clinically proven to be revealed by ERG testing, we are hearing encouraging reports from researchers who are exploring innovative new applications of electrophysiology.”
ABOUT LKC TECHNOLOGIES
When vision issues impact your everyday life, LKC Technologies is here to help. Building on over 40 years of experience in the visual electrophysiology field, our flagship product, the RETeval™ device is transforming the industry for adults and children alike. Eye care professionals and researchers around the world are talking about this revolutionary handheld ERG device from LKC Technologies. Offering full flash and flicker ERG and VEP testing to gather objective, functional data within minutes, the RETeval™ device brings comprehensive electrophysiology technology to any office or clinical setting. LKC Technologies is committed to developing innovative products that lead to the preservation and treatment of sight. LKC Technologies: Vision Defined™. Visit www.LKC.com for more.